论文部分内容阅读
本文报道我院１９７８年１月～１９９２年７月间经外科治疗、病理证实的女性肺癌２１０例，占同期收治肺癌的２０．８％，男女比例为３．８：１。女性肺癌有其明显的临床特点：１．发病年龄低于男性，年龄越小女性肺癌比例越大，＜３０岁者女性占４３．５％（１０／２３）；２．肺癌的组织类型中，女性腺癌发生率最高达４４．８％，鳞癌占２２．４％，与男性肺癌相比较其腺癌、类癌及其他低恶性肿瘤发生率较高（Ｐ＜０．０１），无大细胞癌；３．女性肺癌切除率为７７．１％，低于男性，手术死亡率４．３％，高于男性；４．切除术后１、３、５年生存率为７４．１％，３９．３％及３４．４％，均高于男性。预后较好可能与女性腺癌细胞浆中雌激素激体有关，其性别可作为估计预后的一个因素。
In this paper, 210 cases of female lung cancer confirmed by surgical treatment and pathology in our hospital from January 1978 to July 1992 were reported, accounting for 20.8% of lung cancer patients treated at the same time. The ratio of male to female was 3.8:1. Female lung cancer has its obvious clinical features: 1. The age of onset was lower than that of males, the younger the proportion of females with lung cancer was, the greater the percentage of women aged <30 was 43.5% (10/23). Among the tissue types of lung cancer, the highest incidence rate of female adenocarcinoma is 44.8% and squamous cell carcinoma is 22.4%. The incidence of adenocarcinoma, carcinoid and other low-grade tumors is higher than that of male lung cancer (P<0). .01), no large cell carcinoma; 3. The female lung cancer resection rate was 77.1%, which was lower than that of males. The operative mortality rate was 4.3%, which was higher than that of males. The 1-, 3-, and 5-year survival rates after resection were 74.1%, 39.3%, and 34.4%, both higher than those of men. A good prognosis may be related to the estrogen excitons in female adenocarcinoma cells, and the sex can be used as a factor to estimate the prognosis.